327 related articles for article (PubMed ID: 21847041)
1. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Stewart DJ; Erasmus JJ
J Thorac Oncol; 2011 Jul; 6(7):1149-51. PubMed ID: 21847039
[No Abstract] [Full Text] [Related]
3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
5. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
6. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Kashima J; Okuma Y; Miwa M; Hosomi Y
Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
[TBL] [Abstract][Full Text] [Related]
8. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
[TBL] [Abstract][Full Text] [Related]
10. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Giuliani J; Martelli S; Remo A; Bonetti A
Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Li MX; He H; Ruan ZH; Zhu YX; Li RQ; He X; Lan BH; Zhang ZM; Liu GD; Xiao HL; Wu Y; Zhu B; Wang G; Yang ZZ
BMC Cancer; 2017 Apr; 17(1):245. PubMed ID: 28376735
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Song Z; Zhang Y
J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
[TBL] [Abstract][Full Text] [Related]
13. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
[TBL] [Abstract][Full Text] [Related]
15. Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
Bahce I; Smit EF; Lubberink M; van der Veldt AA; Yaqub M; Windhorst AD; Schuit RC; Thunnissen E; Heideman DA; Postmus PE; Lammertsma AA; Hendrikse NH
Clin Cancer Res; 2013 Jan; 19(1):183-93. PubMed ID: 23136193
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Benedetti G; Latini L; Galetta D; Colucci G; Crinò L
J Thorac Oncol; 2009 Jul; 4(7):936-7. PubMed ID: 19550250
[No Abstract] [Full Text] [Related]
17. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
19. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
20. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan M; Narita N; Tominaga T
BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
